IMAB I-Mab Biopharma: Earnings per share for the last 12 months

I-Mab Inc. (IMAB) - corporate logo

The price action of I-Mab (IMAB) securities reflects the EPS TTM dynamics, which currently stand at 0.00. I-Mab leverages patent protection and low demand sensitivity to therapy costs, utilizing a combination of Chinese R&D centers and a US clinic. Business development depends on the effectiveness of the immunological portfolio, government support, and external financing. Expected results from new tests will provide a key catalyst following the completion of asset reorganization.

I-Mab Inc. (IMAB) Earnings per share for the last twelve months: for the period 02/11/2024 - 02/20/2024

IMAB (I-Mab Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
Market Price I-Mab|IMAB - Price Target Chart
- company stock capitalization data:
Market Capitalization I-Mab Biopharma Co., Ltd.|IMAB - Enterprise Value
- book capitalization indicators:
Accounting Value per Share I-Mab|IMAB - Company Book Value|Market-to-Book Ratio i-mabbiopharma.com|IMAB - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Equity I-Mab|IMAB - Long-Term Debt to Equity|Current Liabilities to Capital I-Mab|IMAB - Company Aggregate Debts|Debt to Net Assets I-Mab Biopharma Co., Ltd.|IMAB - Company Long-Term Liabilities|Short-Term Debt I-Mab|Intermediate Coverage Ratio i-mabbiopharma.com
- earnings and market multiples details:
IMAB - Net Income|Future Net Profit I-Mab|IMAB - P/E Multiple|Future Price to Earnings Multiple I-Mab|IMAB - PEG Multiple|Company Value to EBITDA I-Mab Biopharma Co., Ltd.|IMAB - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year I-Mab|IMAB - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth i-mabbiopharma.com|IMAB - Earnings per share growth in current year|Net earnings per share change forecast for next year I-Mab
- revenue and sales details:
IMAB - Company Sales|Company Expected Sales Volume I-Mab|IMAB - P/S Multiple|Market Cap to Expected Sales Ratio I-Mab Biopharma Co., Ltd.
Fundamental company valuation:IMAB I-Mab Biopharma
Flagship merchandise of I-Mab Biopharma Co., Ltd.

I-Mab has transitioned to the autonomous development of its US oncology programs following the spin-off from its Chinese division. This transformation is reflected in the trend of the rolling annual growth rate of net income per share. This metric measures the percentage change in TTM earnings, allowing the separation of speculative noise from real growth in business efficiency. An analysis of the 12-month YoY net income per share change reveals whether the model is resilient or subject to one-time anomalies.

Direct competitors

Net earnings per one share for the last twelve months incyte.com|HUTCHMED (HCM) - Earnings per share for the last twelve months|Earnings per share for the last 12 months NUVB|DAWN (Day One Bio) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Monopar Corp (MNPR)|Earnings per share for the last twelve months Inhibrx Biosciences (INBX)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics, Inc. HRTX|Nuvectis Pharma Inc. - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals, Inc.|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year beyondspringpharma.com BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology Holdings Inc. LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals)|CLRB (Cellectar Corp) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (canfite.com)|Aprea - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (Kazia Therapeutics)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana (NCNA)|Earnings per share for the last twelve months Chimerix, Inc.|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Inc (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Corp) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months